» Articles » PMID: 3261029

Complement (C3) Metabolism in Rheumatoid Arthritis in Relation to the Disease Course

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 1988 Jan 1
PMID 3261029
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic turnover studies of the third component of complement, C3, were performed in 23 patients with rheumatoid arthritis (RA) to get a direct insight in the dynamics of complement synthesis and catabolism. Results of these turnover studies were related to the serum level of the total amount of C3 as well as to that of the activation product C3d. A hypercatabolism of C3 was observed in 12 of the 23 patients studied. Six of these 12 patients showed signs of extra-articular RA; only one patient with extra-articular manifestations had a normal catabolism of C3. Decreased serum levels of C3 were not found in any of the patients with a hypercatabolism of C3, indicating that the accelerated turnover was compensated by an increased synthesis. In RA patients levels of the activation product C3d could not correlate with the turnover of C3. However, in selected RA patients without signs of nodules or extra-articular manifestations, they could. Thus, our results indicate that serum levels of C3 and C3d do not reflect C3 metabolism in RA patients. Furthermore, the existence of extra-articular manifestations is accompanied by a more pronounced activation of the complement system.

Citing Articles

Rheumatoid arthritis and systemic lupus erythematosus: Pathophysiological mechanisms related to innate immune system.

Pabon-Porras M, Molina-Rios S, Florez-Suarez J, Coral-Alvarado P, Mendez-Patarroyo P, Quintana-Lopez G SAGE Open Med. 2022; 7:2050312119876146.

PMID: 35154753 PMC: 8826259. DOI: 10.1177/2050312119876146.


Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients.

Anand D, Kumar U, Kanjilal M, Kaur S, Das N Clin Exp Immunol. 2014; 176(3):327-35.

PMID: 24433281 PMC: 4008976. DOI: 10.1111/cei.12274.


Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.

Freysdottir J, Ormarsdottir S, Sigfusson A Clin Exp Immunol. 1993; 94(2):286-90.

PMID: 8222319 PMC: 1534224. DOI: 10.1111/j.1365-2249.1993.tb03445.x.

References
1.
Petz L, Powers R, Fries J, Cooper N, HOLMAN H . The in vivo metabolism of the third component of complement in systemic lupus erythematosus. Arthritis Rheum. 1977; 20(7):1304-13. DOI: 10.1002/art.1780200702. View

2.
Abel T, Andrews B, Cunningham P, Brunner C, Davis 4th J, Horwitz D . Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980; 93(3):407-13. DOI: 10.7326/0003-4819-93-3-407. View

3.
Zubler R, LANGE G, Lambert P, MIESCHER P . Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. J Immunol. 1976; 116(1):232-5. View

4.
ROPES M, BENNETT G, COBB S, JACOX R, JESSAR R . 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958; 9(4):175-6. View

5.
De Ceulaer C, Papazoglou S, Whaley K . Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and skynovial membrane cells from patients with rheumatoid arthritis. Immunology. 1980; 41(1):37-43. PMC: 1458236. View